Skyepharma PLC (LSE:SKP) - Share price - Overview

Stock Report

Skyepharma PLC SKP

Last Price
£-

Day Change
-|-%

As of -
- | GBP
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap469.20Mil
52-Wk Range-
Yield %-
ISINGB00B3BFNB64
Volume-
P/E-
P/S-
P/CF-

Share Price

Financials
201320142015
More ...
Income Statement
Revenue62.6073.8095.90
Operating Income13.6021.6031.50
Net Income0.80-10.5026.30
Basic EPS0.02-0.120.25
Avg. Diluted Shares Outstanding4885107
Balance Sheet
Current Assets40.8059.4065.40
Non Current Assets33.8031.6037.80
Total Assets74.6091.00103.20
Current Liabilities33.5039.0038.00
Total Liabilities139.2063.8053.30
Total Equity-64.6027.2049.90
Cash Flow
Operating Cash Flow14.2029.9025.20
Capital Expenditure-3.50-2.90-4.50
Free Cash Flow10.7027.0020.70

In millions, except "Basic EPS". Currency is GBP.

Company Profile

Skyepharma PLC is engaged in the research and development, manufacture and sale of prescription pharmaceutical products. It develops oral and inhalation pharmaceutical products.

Sector

Healthcare

Industry

Drug Manufacturers - Major

Stock Style

Small-Value

Fiscal Year Ends

December

Employees

106
Key Stats
More ...
Price/Earning TTM-
Price/Book-
Price/Sales TTM-
Rev Growth (3 year avg)24.33
EPS Growth (3 year avg)-
Operating Margin % TTM32.85
Net Margin % TTM27.42
ROE TTM68.22
Debt/Equity0.10
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.